Ivonescimab + Paclitaxel for Cancer

This trial tests the safety and effectiveness of combining Ivonescimab and Intraperitoneal Paclitaxel (a type of chemotherapy) for individuals with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA). The trial investigates whether these treatments can work together to control the cancer. Participants with this cancer type, who have undergone no more than two previous treatments and are in good overall health, may be suitable for this trial. As a Phase 2 trial, the research measures how well the treatment works in an initial, smaller group of people.

Previous research has shown that intraperitoneal paclitaxel (IP PTX) is generally safe. Common side effects, such as hair loss and anemia, affect 75% and 60% of patients, respectively, and are usually manageable. Most studies suggest that IP PTX is a safe treatment option for various types of cancer.

Early studies on ivonescimab have also shown promising safety results. The treatment has a manageable safety profile, with serious side effects occurring in about 7% of patients, similar to other treatments like pembrolizumab. Overall, ivonescimab appears well-tolerated when used with chemotherapy.

Unlike the standard treatments for cancer, which often involve systemic chemotherapy, this new approach combines intraperitoneal paclitaxel with ivonescimab. Ivonescimab is a novel drug that targets specific pathways involved in tumor growth and immune evasion, potentially enhancing the body's immune response against cancer cells. The unique delivery method of paclitaxel directly into the peritoneal cavity allows for higher concentrations at the tumor site, potentially increasing effectiveness while minimizing systemic side effects. Researchers are excited about this combination because it targets the tumor environment more precisely, which may improve outcomes for patients with fewer side effects compared to traditional chemotherapy.

Research has shown that intraperitoneal paclitaxel holds promise for cancer treatment. In one study, patients with advanced stomach cancer who received this treatment lived an average of 19.4 months. Another study found that this treatment significantly slowed tumor growth in appendiceal cancer models. Ivonescimab, another treatment in this trial, has demonstrated potential in extending the lives of people with non-small cell lung cancer, showing better results in delaying cancer progression compared to other treatments. This trial will evaluate the combination of intraperitoneal paclitaxel and ivonescimab, which together may effectively combat cancers like appendiceal cancer.¹²³⁴⁵